Protalix Biotherapeutics Inc (PLX)
R&D Expense Growth
-19.81%
Quarterly · Period ending:
PLX R&D Expense Growth
Latest reported-19.81%period ending
Latest reported-19.81%period ending
PLX Quarterly R&D Growth (QoQ) (0.00% → -19.81%)
Latest values, visible window
High-resolution chart · PNG
PLX r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| -19.812% | |
| -3.709% | |
| 26.1473% | |
| -25.4506% | |
| 72.4317% | |
| -15.7371% | |
| 37.5583% | |
| 1.2496% | |
| 2.5632% | |
| -6.931% | |
| -15.4538% | |
| -18.0112% | |
| -23.465% | |
| 4.0947% | |
| -23.9507% | |
| -2.5465% | |
| -13.5508% | |
| 14.7363% | |
| 4.93% | |
| -5.2933% | |
| 7.9612% | |
| -34.9767% | |
| 42.4688% | |
| -16.3074% | |
| -11.1605% | |
| 7.7645% | |
| -4.05% | |
| -24.9418% | |
| 13.8913% | |
| 17.3438% | |
| -1.0128% | |
| 39.083% | |
| 12.3855% | |
| -28.3315% | |
| 40.7106% | |
| -27.6116% | |
| 90.6675% | |
| -18.9033% | |
| 12.8956% | |
| -35.337% | |
| 29.7759% | |
| -21.7329% | |
| 46.3498% | |
| -18.7143% | |
| -4.3035% | |
| 49.7343% | |
| -26.0278% | |
| 23.0351% | |
| -18.2133% | |
| -17.9913% | |
| 31.24% | |
| -12.7129% | |
| 21.3226% | |
| -32.5263% | |
| 23.9824% | |
| -28.1423% | |
| 29.3834% | |
| -9.1705% | |
| -4.8371% | |
| 8.1842% | |
| -11.5101% | |
| -13.4742% | |
| 169.5713% | |
| -64.632% | |
| 36.4453% | |
| -13.8671% | |
| 85.0141% | |
| -1.9353% | |
| 23.9325% | |
| -21.4167% | |
| -10.6588% | |
| 87.5087% | |
| -32.7735% | |
| -10.501% | |
| 39.0421% | |
| 21.6455% | |
| 57.8595% | |
| -52.4516% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |